NCT07220954CompletedPhase 1
A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234
A Phase I, Single-Dose, Open-Label, Sequential, Randomised, Crossover Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD6234 in Participants Living With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will enrol 21 healthy men and women aged 18-55 years.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- First submitted
- 23 Oct 2025
- Start date
- 11 Nov 2025
- Primary completion date
- 16 Sept 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Obesity
- NCT number
- NCT07220954
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 19
- From 11 Nov 2025 to the primary completion date, 16 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any participant who has received an amylin analogue containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer)
- Participants who report to have previously received AZD6234.
- Use of any prescribed or non-prescribed medication
Other illness
- History of any clinically important disease or disorder
- History or presence of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric or gastrointestinal disorder including a history of pancreatitis or gall stones
- Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the planned first dosing day
- Evidence of renal impairment
Lab values
- HbA1c ≥6.5% (≥48 mmol/mol)
Other
- Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis
- Any clinically significant abnormal findings in vital signs
- Any clinically significant abnormalities on 12-lead ECG
- Females who are pregnant or lactating.
Who the study is looking for
- Healthy males or non-pregnant, non-lactating females aged 18 to 55 years inclusive
- BMI of 25.0 to 35.0 kg/m2 inclusive and weight ≥50 kg
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Ruddington | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.